Clinical Trial Update: Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

View source ↗

Summary

The document reports efficacy and safety data from long-term use of KOGENATE FS (recombinant factor VIII) for hemophilia A in Latin America.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Kogenate FS (Factor VIII)

Snippet

Sponsor: Bayer | Conditions: Blood Coagulation Disorders, Hemophilia A | Status: COMPLETED